It was evidenced that in vivo administration of agonistic anti-CD40 antibodies resulted in the augmentation of Bregs subset providing IL-10 and amelioration or prevention of arthritis via inhibition of the Th1 response (Evans et al. 2007; Mauri et al. 2000, 2003). This evidence concerns the gene IL10 and arthritic joint disease.